# An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

> clinical trial · VERIFIED · 2026-08-04

Status: AVAILABLE · Sponsor: Alkermes, Inc. · Condition: Bipolar 1 Disorder

- Company: Alkermes, Inc.
- Sector: mental health
- Primary source: https://clinicaltrials.gov/study/NCT07744113

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.